| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.11. | Ramaswamy's biotech baggage haunted his political run | ||
| 09.11. | State incentives for commercial-stage life sciences companies | ||
| 09.11. | Translating Phase II success into Phase III readiness takes more than scale | ||
| 09.11. | Making the 'impossible' executable in life sciences construction | ||
| 06.11. | Novartis reveals cancer cases possibly linked to gene therapy Zolgensma | ||
| 06.11. | Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down | ||
| 06.11. | This week in charts: 3 drug launches Wall Street is watching | ||
| 05.11. | Medicare will cut billions from 340B, expand site-neutral payments in 2027 | ||
| 05.11. | At ASH, drugmakers to showcase early data for three-pronged cancer therapies | ||
| 05.11. | Revolution's Rasonque off to best cancer drug launch 'in history' | ||
| 05.11. | T-Therapeutics reloads with a $133M megaround for bispecifics | ||
| 05.11. | Alethio raises $90M to target rare blood cancers | ||
| 04.11. | Sanofi stops development of Nurix-partnered immune drug | ||
| 04.11. | Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts | ||
| 04.11. | CVS to split into two companies in stunning strategic about-face | ||
| 04.11. | Biopharma likely to climb higher after 'blue wave,' analysts say | ||
| 03.11. | Vertex, ahead of FDA decision, calms fears surrounding kidney drug | ||
| 03.11. | UniQure gets an FDA decision date; Teva scraps brain drug study | ||
| 03.11. | Medicare Part D premiums are spiking 50% on average next year, KFF finds | ||
| 02.11. | Karyopharm, deep in debt, to sell itself in bankruptcy | ||
| 02.11. | Keytruda biosimilars are coming - but they face an uphill battle | ||
| 02.11. | Earnings roundup: AstraZeneca's cost cuts, Alnylam's slump and Regeneron's resilience | ||
| 02.11. | Breaking the silos: What effective scenario modeling looks like in 2026 and beyond | ||
| 30.10. | This week in charts: ESMO's winners and losers | ||
| 30.10. | With Setara, the team behind Actio opens its second act |